What they call their work
What they do
-
Cancer Research Funding 2 activities
- Conducting and advancing research on aging and cancerConducts and supports research on the biological links between aging and cancer, including studies on biological aging measurement, age-related immune decline, inflammation, senescent cells, and cancer-prone cell expansion, with the goal of improving cancer prevention, early detection, and age-appropriate treatments.
- Funding innovative cancer research through grantsFunds innovative cancer research to accelerate the development of cures for patients by awarding grants to leading researchers and supporting high-risk, high-reward projects in collaboration with partners such as the Cancer Research Institute and The Mark Foundation for Cancer Research.
-
-
Advancing Geroscience Research and Translation 1 activity
- Building global research capacity in aging and cancerStrengthens international scientific collaboration by launching initiatives such as the International Network on Aging and Cancer (2018) and co-founding the International Center for Aging and Cancer in Hainan, China, to connect researchers, train scientists, and promote interdisciplinary exchange across fields including genomics, immunology, metabolism, and artificial intelligence.
-
Who runs it
| Name | Title | Hours/wk | Compensation |
|---|---|---|---|
| WILLIAM T SULLIVAN | EXECUTIVE DIRECTOR | 50 | $431K |
| SAMUEL WAXMAN MD | DIRECTOR-CEO | 20 | $250K |
| KAREN KIRK | DIRECTOR OF SPECIAL EVENTS | 40 | $194K |
| GREGORY FABIJANCZUK | CFO/DIRECTOR OF FINANCE (thru 04/30/2025) | 40 | $188K |
| WYLIE TENE | DIRECTOR OF MARKETING & COMMUNICATION | 40 | $172K |
| Suzanna C Houston | Director of Special Projects | 40 | $162K |
- ARI ZAGDANSKI — DIRECTOR
- BARON SILVERSTEIN — DIRECTOR
- CHRISITNE ARLOTTA — DIRECTOR
- DENA K WEINER — VICE-PRESIDENT
- DENNIS A HERMAN — DIRECTOR
- ETHAN DMITROVSKY MD — DIRECTOR
- FREDRICK W BARNEY — DIRECTOR
- GARY JACOB — DIRECTOR
- GARY NOLAN — DIRECTOR
- GERARD J JOYCE — SECRETARY
- HOWAD SHLAFMITZ — DIRECTOR
- JAMES A INGRAM — DIRECTOR (THRU 02/01/2025)
- JAMES FRANKEL — DIRECTOR
- JOSEPH STEFFA — DIRECTOR
- KENNETH FISHEL — DIRECTOR (THRU 05/01/2025)
- LEWIS A RUBIN — DIRECTOR
- LINDA HERMAN — DIRECTOR
- MARC TAUB — DIRECTOR
- MICHAEL NIERENBERG — CHAIRMAN
Who they work with
- Albert Einstein College of Medicine Partner — Joined the International Network on Aging and Cancer in 2023.
- Cancer Research Institute Partner — Co-funder of research projects
- Hainan Medical University Partner — Co-founded the International Center for Aging and Cancer in Hainan, China.
- Icahn School of Medicine at Mount Sinai Partner — Institution where Dr. Samuel Waxman conducted research and hosted Chinese scientists for training in cell differentiation.
- Israel Cancer Research Fund Partner — Joined the International Network on Aging and Cancer in 2023.
- Johns Hopkins Bloomberg School of Public Health Partner — Partners with Johns Hopkins Bloomberg School of Public Health through advisory committee membership in cancer biology and biochemistry.
- Melanoma Research Alliance Partner — Joined the International Network on Aging and Cancer in 2023.
- Montefiore Einstein Comprehensive Cancer Center Partner — Collaborates with the Montefiore Einstein Comprehensive Cancer Center through shared research leadership in cancer dormancy and tumor microenvironment.
- National Cancer Institute Partner — Partnered through the Partnership for Aging and Cancer Research Program to study shared biological mechanisms between aging and cancer.
- National Institute on Aging Partner — Partnered through the Partnership for Aging and Cancer Research Program to study shared biological mechanisms between aging and cancer.
- Ruijin Hospital of Shanghai Jiao Tong University School of Medicine Partner — Co-founded the International Center for Aging and Cancer in Hainan, China.
- Shanghai Institute of Hematology Partner — Collaborated with Dr. Waxman on developing trans-retinoic acid treatment for APL.
- Shanghai Second Medical University Partner — Hosted visiting scientists trained in Dr. Waxman's lab and collaborated on early APL research.
- Stanford University School of Medicine Partner — Engages with Stanford University School of Medicine through advisory committee membership focused on cancer research.
- The Mark Foundation Funder — Collaborates with and receives support from The Mark Foundation for research initiatives.
- The Mark Foundation Partner — Collaborates with the Samuel Waxman Cancer Research Foundation, as indicated by logo presence and partnership affiliation.
- The Mark Foundation Partner — Collaborates with the Samuel Waxman Institute for Aging & Cancer in advancing research on aging and cancer.
- The Mark Foundation Partner — Collaborating organization in the initiative focused on aging and cancer research
- The Mark Foundation for Cancer Research Partner — Affiliate organization co-supporting the Samuel Waxman Institute for Aging & Cancer.
- The Mark Foundation for Cancer Research Partner — Collaborative partner in creating the Samuel Waxman Institute for Aging & Cancer; SWCRF merged operations under this affiliate structure.
- The Mark Foundation for Cancer Research Partner — Collaborative relationship indicated by shared board membership and co-branded presence on leadership page
- The Mark Foundation for Cancer Research Partner — Partners with The Mark Foundation for Cancer Research through shared scientific leadership and advisory roles.
- The Mark Foundation for Cancer Research Partner — Samuel Waxman Institute for Aging & Cancer is an affiliate of The Mark Foundation for Cancer Research.
- University of California, San Francisco Partner — Collaborates with University of California, San Francisco via Scientific Advisory Committee involvement in pharmacology and cancer research.
- University of Colorado Anschutz Medical Campus Partner — Collaborates with University of Colorado Anschutz Medical Campus on lung cancer research through Scientific Advisory Committee membership.
- Van Andel Institute Partner — Engages with Van Andel Institute through leadership participation in scientific advisory activities.
- Wiley Publishing Partner — Partnered to launch Aging and Cancer, the first peer-reviewed journal dedicated to research on the biological links between aging and cancer.
- academic institutions Partner — Partners with academic institutions to co-fund research and align resources on shared scientific priorities in aging and cancer.
- foundations Partner — Builds partnerships with foundations to amplify investment and expertise in aging and cancer research.
- governmental agencies Government — Partners with governmental agencies to strengthen the global research ecosystem for aging and cancer.
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Collaborative Funding to Leverage Research Investmentmethodology: collaborative_fundingBy co-funding research with external partners, the foundation amplifies its impact, because shared financial and scientific resources enable larger, more ambitious research initiatives than single-organization funding allows.
- Interdisciplinary and Global Scientific Collaborationmethodology: interdisciplinary_collaborationBy uniting researchers across aging biology and oncology disciplines—nationally and internationally—the foundation accelerates discovery, because complex challenges in cancer and aging require integrated expertise and open knowledge sharing.
- Targeting Aging as a Central Driver of Cancermethodology: aging-as-central-mechanismBy studying the biology of aging as a root biological mechanism, the foundation aims to accelerate cancer prevention, early detection, and treatment breakthroughs, because aging shares fundamental pathways with cancer development and treatment response.
- Translational Research from Biology to Clinical Impactmethodology: translational-researchBy translating discoveries in aging and cancer biology into clinical tools and therapies, the foundation drives patient benefit, because bridging basic science and medical application ensures research delivers real-world outcomes.